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Introduction 
Although representing approximately 2% of the total body weight, the human brain 
demands around 20% of the cardiac output when the body is at rest. As storage of 
oxygen, glucose and other substrates necessary for energy metabolism in the brain is 
limited, a continuous cerebral blood supply is of major importance. Consequently, the 
brain is extremely sensitive to even brief disruptions in blood flow. Focal ischemia 
occurs when a specific area of the brain suffers due to a critical reduction in blood 
flow. This reduction is often caused by an obstruction, typically a clot creating an 
occlusion of the cerebral arteries. Depending on the severity and location of the 
induced ischemia, neurological deficits may occur within short time. Persistent 
ischemia leads to death of cerebral tissue, cerebral infarction. The dissolution of the 
clot and reopening of the occluded vessel is called recanalization. Early 
recanalization may lead to reperfusion of ischemic tissue and reversibility of 
neurological deficits. Whether occurring spontaneously or induced by thrombolytic 
agents, recanalization represents an important goal of ischemic stroke treatment and 
is often critical in order to achieve a favorable outcome after cerebral ischemia.  
 
Transient ischemic attack 
Definition  
Neurological deficits caused by cerebral ischemia may be reversible if recanalization 
is achieved and blood flow rapidly restored. Neurological deficits caused by ischemia 
typically include unilateral loss of motility, coordination, sensation or impaired 
ability to speak. Due to the prompt reversibility of symptoms, this disease is called 
transient ischemic attack (TIA). TIA may in this way be regarded as the ultimate 
successful clinical course of cerebral ischemia. Originally, TIA was defined as a 
“cerebral dysfunction of ischemic nature lasting no longer than 24 hours with a 
tendency to recur”.1, 2 In 1975, when this definition was formulated, there were no 
imaging techniques available on a routine basis to confirm the existence of cerebral 
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ischemia. The definition was therefore based on the assumption that the ischemia had 
resolved rapidly enough to only cause transient symptoms and no permanent brain 
injury. The 24-hour duration was chosen without supporting data.2, 3 The definition of 
TIA proposed in 1975 is still in use today. We know, however, that the 24-hour time 
limit does not reflect the normal duration of these events. A study published two 
years after the original definition showed that the median duration of TIAs was 14 
minutes for ischemia within the carotid artery territory and 8 minutes for posterior 
circulation territory.4 Another study reported that 86% of those who had ischemic 
symptoms lasting longer than one hour still had persisting symptoms after 24 hours.5 
In a pooled analysis, 60% of TIAs lasted less than 1 hour, 71% less than 2 hours and 
86% less than 6 hours.6 These data indicate that the majority of TIAs are shorter than 
one hour in duration. In this context, the 24-hour time limit is misleading and does 
not reflect the normal duration of these events. With the development of better 
imaging techniques in stroke diagnostics we also know that a number of patients with 
an apparent TIA demonstrate ischemic lesions on neuroimaging. Patients may in 
other words have both TIA and cerebral infarction at the same time. These findings 
contradict the traditional concept of TIA as being transient and without any sign of 
infarction. This has led to a proposal of a new tissue-based TIA definition: “a 
transient episode of neurological dysfunction caused by focal brain, spinal cord, or 
retinal ischemia without acute infarction”.7  
This definition has been welcomed by many. The time limit has been removed and 
the difference between ischemic stroke and TIA is based on the evidence of 
infarction. This tissue-based definition is in harmony with the definitions of ischemic 
injuries to other organs. In ischemic heart disease, angina pectoris is not separated 
from myocardial infarction based on symptom duration but whether tissue damage is 
evident or not. Critics have, on the other side, argued that a new tissue-based 
definition will lead to different incidence rates of TIA and ischemic stroke depending 
on availability of brain imaging. MR diffusion-weighted imaging (DWI) is in this 
context especially relevant, considering its ability to detect ischemic damage.   
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Diffusion-weighted imaging and TIA 
DWI is highly sensitive in detecting ischemic cerebral injury and the only imaging 
technique able to reliably demonstrate lesions within minutes after onset of cerebral 
ischemia.8 The technique is based on the ability to detect self-diffusion of water, also 
known as Brownian motion. These movements are restricted in ischemic brain tissue 
due to the rapidly developing cytotoxic edema. Different sets of images are obtained 
in DWI, one or more with diffusion weighting and one without diffusion weighting 
(T2-sequence).9 A dephasing and subsequent re-phasing of the spinning protons in 
water molecules are produced by a bipolar pair of diffusion-sensitizing magnetic field 
gradient pulses to the T2-sequence. A net displacement of a water molecule between 
these two pulses results in a signal loss in the image. This means that the signal loss is 
proportional to water movement. In ischemic tissue, water movement or diffusion is 
reduced. The lesion with reduced diffusion is identified as an area of signal increase 
compared to the hypointense normal brain parenchyma. 
Patients with transient ischemic symptoms frequently demonstrate DWI lesions, even 
though neurological deficits are reversible.10 Studies have shown ischemic lesions in 
21-68% of patients with an apparent TIA.11 Important questions arise with these 
results. Why do some patients with transient ischemic symptoms have DWI lesions 
while others have normal DWI findings? And is DWI lesion distribution different in 
DWI positive patients with transient symptoms as compared to those with persistent 
symptoms? Prior studies have shown that lesions are typically solitary and smaller in 
patients with transient symptoms as compared to those with persistent symptoms.12 
However, no studies have shown a specific predilection for DWI lesion location or 
distribution in patients with transient symptoms.7 Some studies have compared 
patients with transient ischemic symptoms with or without DWI lesions, but with few 
consistent findings.11 Clinical features, such as longer symptom duration, motor 
deficits and aphasia have been associated with DWI positivity in patients with an 
apparent TIA.13-15 Other studies have also found an association with large artery 
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disease and cardioembolism, suggesting a higher chance of DWI lesions in patients 
with these stroke mechanisms.16, 17  
 
DWI lesions and irreversible damage 
It has been discussed whether DWI lesions really represent irreversible injury in the 
setting of TIA. If the answer is no, patients with transient symptoms and DWI lesions 
may still be classified as TIA using a tissue-based definition because both symptoms 
and DWI lesions are transient. Few studies have investigated reversibility of DWI 
lesions in patients with an apparent TIA. Three series have been performed, of which 
one study included 11 patients with transient ischemic symptoms and DWI lesions.18 
Follow-up MRI with T2 weighted imaging was performed within 2-9 days after 
symptom debut. All 11 patients with DWI lesions had corresponding lesions on 
follow-up. Another study included 20 patients with an apparent TIA and DWI 
lesions, of which 6 had MRI two to seven months after the event.10 A total of 3 
patients had corresponding lesions. The largest series included 33 patients with 
transient ischemic symptoms and DWI lesions who completed follow up MRI after 
approximately 10 months.19 A total of 26 patients (79%) had infarctions 
corresponding to the original DWI abnormalities. The authors concluded that most of 
the DWI lesions represented irreversible damage and therefore supported a tissue-
based TIA diagnosis. Animal studies have also demonstrated underlying histological 
tissue damage even though early DWI lesions reversed.20, 21 It may thus be claimed 
that DWI positive patients with transient symptoms and normal follow-up T2 
sequences still could be interpreted within the tissue-definition as ischemic stroke and 
not as TIA.   
 
The link between TIA and ischemic stroke 
TIA and ischemic stroke were previously considered as two entirely different 
conditions.7 Health workers and the public often regarded TIA as a benign condition 
as compared to ischemic stroke, which was something serious. In recent years, 
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especially with the implementation of DWI into TIA- and stroke diagnostics, the link 
between TIA and ischemic stroke has proved to be closer than previously thought. 
These conditions are now by many considered as parts in a spectrum involving a 
serious state of cerebral ischemia. The majority of TIAs and ischemic strokes are 
caused by an occlusion where the transient nature of symptoms is the result of early 
recanalization and reperfusion. In contrast to ischemic stroke, TIA offers an 
opportunity to prevent permanent disability if the symptoms are taken seriously.  
 
In total, 15-26% of patients with ischemic stroke have a history of TIA.22 A majority 
of these patients experienced the TIA within short time before ischemic stroke onset. 
A total of 17% had TIA on the same day as the stroke, 9% on the day before and 43% 
at some point during the week before stroke onset. These observations highlight the 
risk of recurrent ischemic events after TIA. Attempts have been made to quantify the 
risk of ischemic stroke after TIA based on clinical observations, such as the ABCD2 
score.23 The ABCD system was primarily developed to assist primary care physicians 
in triaging patients with suspected TIA. In ABCD2, patients with an apparent TIA 
may score between 0 and 7 points based on the following factors: age t60 years (1 
point), blood pressure t140/90 mm Hg (1 point), duration t60 minutes (2 points) or 
10-59 minutes (1 point), symptoms with hemiparesis (2 points) or aphasia (1 point) 
and, finally, presence of diabetes mellitus (1 point). The 2-day risk of stroke range 
between 0% for the lowest scores (0-1) and 8.1% for the highest (6-7). The presence 
of DWI lesions in patients with transient symptoms is also strongly associated with 
an increased short-term risk of further vascular events. 24 This has led to the inclusion 
of DWI lesions in a new score developed for risk stratification in secondary care: the 
ABCD3 score. 25 
The precision of these scores may be explained by the lower scores achieved in 
patients with mimics as compared to the higher scores of those with a true vascular 
etiology.  Mimics represent 31-40% of TIA referrals to secondary healthcare 
institutions.26, 27 As the gold standard for TIA remains the judgment of a vascular 
neurologist, the diagnosis of TIA is often subjective and difficult.28 In this setting, 
  
15 
15 
DWI proves itself as a useful tool to “catch” patients with a definite vascular 
etiology. Some of these patients could be interpreted as stroke mimics if DWI is not 
routinely performed in all patients with apparent TIA.  
 
Ischemic stroke 
Definition 
The current World Health Organization definition of stroke was introduced in 1970 
and is still in use today. It defines stroke as “rapidly developing clinical signs of focal 
(or global) disturbance of cerebral function, lasting more than 24 hours or leading to 
death, with no apparent cause other than that of vascular origin”. 29 With the proposal 
of a tissue-based TIA definition, a new definition of ischemic stroke has also emerged 
as “an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal 
infarction.”30 Infarction is here defined as cell death based on objective evidence of 
ischemic injury, such as pathological or imaging evidence, or clinical evidence of 
ischemic injury based on persisting symptoms ≥24 hours or until death where other 
etiologies are excluded. This broad definition includes clinical vascular symptoms 
≥24 hours in addition to evidence of ischemic injury at any time, regardless of 
symptom duration. The updated definition is similar to the definition used in the 
present thesis where ischemic stroke was defined in accordance to the Baltimore-
Washington Cooperative Young Stroke Study Criteria as “neurological deficits 
lasting more than 24 hours because of ischemic lesions or clinical TIA where 
neuroimaging showed infarction related to the clinical findings”.31  
 
Burden of ischemic stroke 
Unlike TIA, ischemic stroke often leads to permanent neurological deficits and 
disability. Ischemic stroke has been rated as the third most common cause of death in 
the world and a major cause of disability requiring long-term institutionalization.32 
Patients with ischemic stroke are at highest risk of death within the first 30 days after 
symptom onset.33 Higher age and comorbidities such as ischemic heart disease and 
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diabetes mellitus increase risk of poor outcome.34 Outcome is also highly dependent 
on stroke location and volume. A complete middle cerebral artery infarction often has 
a worse outcome than an incomplete infarction within the same arterial territory. On 
the other hand, a strategic small lacunar infarction in the brain stem may have a far 
worse prognosis than a large supratentorial cortical infarction. Outcome after 
ischemic stroke is frequently measured by using the modified Rankin Scale 
(Appendix, figure 1). Favorable outcome is often categorized as mRS 0-1 or 0-2 on 
discharge or after 3 months, whereas a score of 6 means that the patient died. 
Mortality rates within 30 days range between 2.5% after lacunar infarction to 78% 
after malignant middle cerebral artery infarction.35, 36 Death is most often caused by 
the stroke itself or cardiopulmonary complications.37, 38  
In Norway, cerebrovascular disease is the most common cause for disability among 
elderly and comes after myocardial infarction and cancer as the most frequent cause 
of death.39 The annual Norwegian incidence rate for first-ever and recurrent stroke 
was in 2007 estimated to 11000 and 3500, respectively.39 This analysis included, 
however, intracerebral hemorrhage and subarachnoid hemorrhage. Age remains the 
most important risk factor for ischemic stroke. Approximately 60% of all strokes in 
Norway occur in patients who are older than 75 years.40 An increased stroke 
incidence is expected in the near future due to the increased proportion of elderly in 
the population.39 Other common risk factors for ischemic stroke include hypertension, 
diabetes, cigarette smoking, dyslipidemia, physical inactivity and conditions such as 
atrial fibrillation, internal carotid stenosis and ischemic heart disease. 41-45 Risk 
factors may differ according to stroke subtype.43, 46 
 
Stroke symptoms and severity 
Ischemic stroke is characterized by the sudden onset of focal neurological deficits. 
The specific type of neurological symptoms depends on the vascular territory 
affected. Anterior circulation occlusions typically produce contralateral facial and/or 
extremity weakness and sensory loss. Aphasia or neglect may also be present if the 
superficial cortex is affected. Symptoms of posterior circulation occlusions include 
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hemianopsia, ataxia, diplopia, dysarthria and vertigo in addition to unilateral 
weakness and sensory loss. Consciousness is mostly sustained in anterior circulation 
infarction, but may be impaired if the posterior circulation is affected, especially the 
basilar artery.  
Stroke symptoms on presentation may be categorized and quantified. The 
Oxfordshire Community Stroke Project (OCSP) (Appendix, figure 2) classification 
categorizes stroke symptoms into four different syndromes: lacunar infarcts (LACI), 
total anterior circulation infarcts (TACI), partial anterior circulation infarcts (PACI) 
and posterior circulation infarcts (POCI).47 The classification may prove useful in 
predicting stroke location and outcome, although etiology is not assessed. 48, 49 
A quantitative assessment of ischemic stroke symptoms is provided by the National 
Institutes of Health Stroke Scale (NIHSS) (Appendix, figure 3).50 This scale includes 
11 items with different scores where the total score may correlate with lesion volume 
and clinical outcome.51 The NIHSS score is widely used in rating stroke severity and 
monitoring neurological development after ischemic stroke. However, limitations 
include higher scores for patients with left hemisphere strokes and poor interrater 
agreement in some of the components, such as grading limb ataxia.52, 53   
 
Etiology and pathophysiology  
The majority of ischemic strokes are caused by an arterial occlusion. More rarely, 
ischemic injury may be caused by hypoperfusion due to extra- or intracranial 
stenosis. This is especially relevant in severe carotid disease where watershed 
ischemia can be caused due to hemodynamic impairment.54 New evidence suggests, 
however, that a significant proportion of these infarcts also may be caused by 
microembolism.55  
The Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria is frequently 
used in describing stroke etiology and encompasses five major categories: large-
artery disease, cardioembolism, small vessel disease, stroke of other determined 
cause and stroke of undetermined cause (Appendix, figure 4).56 A German study 
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showed that approximately 15% of ischemic stroke patients had large-artery disease, 
30% cardioembolism, 25% small vessel disease, 2% stroke of other determined cause 
and 40% unknown cause.57 Large-artery disease is a more common cause in older 
patients, whereas younger patients have higher rates of other determined etiologies 
and undetermined etiology. 58  
Regardless of stroke etiology, ischemic brain injury is a common denominator. This 
is the result of blood perfusion below a critical threshold, which leads to energy 
depletion and eventually infarction. The acute arterial occlusion leads to an infarct 
core and a surrounding zone of ischemic penumbra. The central core consists of 
irreversibly damaged cells whereas the penumbral zone is supplied by sufficient 
blood to maintain structural integrity, even though the neurons remain 
dysfunctional.59 The neurological deficits caused by the penumbra may be reversible 
if reperfusion can be achieved within a short time. If reperfusion fails, the penumbral 
zone will turn into infarct as well. The timing of infarction of the penumbral zone is 
dependent on residual blood flow, duration of ischemia and physiological factors, 
such as body temperature and serum glucose.34 This time-window also represents the 
therapeutic window of opportunity in acute ischemic stroke in which recanalization 
can have a major clinical impact by saving neurons from irreversible destruction.  
 
Recanalization 
Recanalization hypothesis 
Recanalization is the major therapeutic aim in patients admitted with acute cerebral 
ischemia. Rapid recanalization leading to reperfusion of threatened ischemic tissue 
improves clinical outcome as compared to no or too late recanalization.60 This 
statement is called the “recanalization hypothesis”. The correlation between 
recanalization and clinical outcome was confirmed in a meta-analysis from 2007 
including 53 studies and 2066 patients. 60There was a four-fold increase in the odds of 
favorable outcome and a four-fold reduction in odds of death within 3 months if 
recanalization was achieved within 24 hours after stroke onset. The earlier 
  
19 
19 
recanalization occurred, the higher were the chances for favorable outcome. Studies 
using Doppler monitoring have shown an association between early recanalization 
and dramatic neurological improvement.61-63 Early improvement by ≥10 NIHSS 
points at 24 hours after symptom onset was associated with either complete or partial 
recanalization, whereas no clinical improvement or worsening indicated failed 
recanalization.62 This major neurological improvement (MNI) may be considered as a 
useful surrogate marker for thrombolytic activity and successful recanalization.64 
Although the correlation between recanalization and favorable outcome has been 
established, recanalization is no guarantee for reperfusion and neurological 
improvement. This phenomenon of “futile recanalization” may occur if recanalization 
is achieved too late, i.e. if there is no penumbra left to salvage.60 Recanalization of 
larger vessels may also result in inadequate reperfusion due to distal smaller 
occlusions originating from multiple embolic fragments of the dissolved primary 
occlusion. In addition, collateral circulation can weaken the recanalization-outcome 
correlation as neurological deficits may be minor if collateral vessels sufficiently 
supply threatened tissue in the presence of a larger occlusion.65 
 
Recanalization and thrombolysis 
Early recanalization is the incitement for thrombolytic therapy. Intravenous 
thrombolytic treatment with tissue plasminogen activator (tPA) was approved by the 
US Food and Drug Administration (FDA) in 1996 and is today routinely used as 
recanalizing treatment for ischemic stroke. TPA or Alteplase is a serine-protease, 
which converts plasminogen into plasmin.66 Plasmin degrades fibrin and is thereby 
essential to the lysis of occluding thrombi, which mostly are made of fibrin in 
combination with platelets and erythrocytes. The relative proportions of thrombus 
components are thought to be based on clot origin. “Red” erythrocyte-and fibrin-rich 
clots are formed in areas with stagnant blood flow whereas “white” platelet-rich clots 
originate from areas of high flow, such as the arterial system.67 Endogenous tPA is 
released from endothelial cells and contributes to the physiological balance between 
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thrombosis and thrombolysis. In the setting of an occluding thrombus, thrombolysis 
commences predominantly within the thrombus or at its surface.68 Exogenously 
applied tPA is dependent on a certain amount of blood flow to reach the thrombus 
surface.61 The following thrombolysis is a process where the clot is dissolved step-by-
step. The first steps of clot dissolution allow blood perfusion further into the 
thrombus, which expose more binding sites for tPA and plasmin. This process may 
continue until complete clot break-up and recanalization is achieved under the 
pressure of arterial pulsations. 
 
Thrombolysis with tPA 
The National Institute of Neurological Disorders and Stroke (NINDS) study group 
demonstrated in 1995 efficacy of ischemic stroke treatment with tPA within 3 hours 
after symptom onset.69 Patients receiving tPA had at least 30% better chance of 
favorable outcome at 3 months as compared to the placebo-group. Symptomatic 
intracerebral hemorrhage (sICH) occurred in 6.4% of patients treated with tPA. 
Efficacy of tPA administered in an extended time window of up to 6 hours was not 
shown in two following European trials: the European Cooperative Acute Stroke 
Study (ECASS) and ECASS II.70, 71 However, a subsequent meta-analysis including 
>2500 stroke patients reported an odds ratio of 1.4 for favorable outcome if tPA was 
administered between 3 hours and 4.5 hours.72 As a result, the ECASS III was 
designed to prospectively test efficacy and safety of tPA administered between 3 to 
4.5 hours after stroke onset.73 This study confirmed an improved outcome of patients 
treated with tPA as compared to placebo with a odds ratio of 1.3. A total of 2.4% had 
sICH. The difference in proportion of sICH between the NINDS trial and ECASS III 
may rely on the different definitions of sICH applied in each of these trials (table 1).   
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Table 1: Common symptomatic intracerebral hemorrhage definitions 
 
 
 
 
 
 
 
 
 
 
 
 
*Hemorrhagic infarction 1 (HI1) is defined as small petechiae along the margins of the infarct; hemorrhagic 
infarction 2 (HI2) as confluent petechiae within the infarcted area but no space-occupying effect; parenchymal 
hemorrhage (PH1) as blood clots in 30% or less of the infarcted area with some slight space-occupying effect; 
and parenchymal hemorrhage (PH2) as blood clots in more than 30% of the infarcted area with substantial 
space-occupying effect.71  
 
Outcomes of thrombolytic treatment may differ in clinical practice as compared to the 
setting of randomized trials. The multinational Safe Implementation of Thrombolysis 
in Stroke-Monitoring Study (SITS-MOST) evaluated safety and efficacy in stroke 
patients treated with tPA in clinical routine settings within 3 hours after stroke 
onset.74 The results confirmed the positive findings of previous randomized trials 
with similar rates of sICH and mortality. However, patients who did not meet the 
conservative pre-specified eligibility criteria were systematically excluded from the 
analysis.75 This proportion of “off-label” tPA treated patients was not reported. It may 
thus be claimed that the results of SITS-MOST represent a too idealized clinical 
situation as compared to the reality in daily clinical practice.  
 
Trial Definition Ref 
NINDS  Any hemorrhage plus any decline in neurologic status  69 
ECASS II Blood at any site in the brain on CT, clinical deterioration or 
adverse events indicating clinical worsening or causing an 
increase in the NIHSS score of 4 points or more 
71 
ECASS III Any apparently extravascular blood in the brain or within the 
cranium associated with clinical deterioration (defined by an 
increase in the NIHSS score of 4 or more points) or death, and that 
is identified as the predominant cause of the neurological 
deterioration 
73 
SITS-MOST Local or remote parenchymal hemorrhage type 2* on the 22-36 
hours post-treatment imaging scan, combined with a neurological 
deterioration of 4 points or more on the NIHSS from baseline or 
from the lowest NIHSS value between baseline and 24 h, or leading 
to death.  
74 
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Off-label thrombolysis 
Although studies have demonstrated safety and efficacy of ischemic stroke treatment 
with tPA, the total numbers of treated patients in clinical practice have been low.76 
Different factors may explain this. A number of stroke patients are admitted to the 
hospital too late to reach the therapeutic time window, although one study showed 
that 50% of ischemic stroke patients may reach a hospital within the 3 hours77  
Treatment with tPA is approved within 3 hours after stroke onset according to 
Norwegian national guidelines (figure 1), although the current time-window has been 
extended to 4.5 hour in clinical practice, based on the ECASS III results.78 If patients 
manage to arrive within this timeframe, several other contraindications remain which 
restrict the use of tPA. The narrow timeframe in combination with other 
contraindications make treatment with tPA only available for a fraction of the total 
number of acute ischemic stroke patients admitted. A study showed that 
approximately 75% of the total number of patients was excluded from thrombolytic 
treatment due to contraindications.79 These contraindications originate from the study 
protocols of prior thrombolytic trials and were designed to include only patients with 
high likelihood of recovery after treatment.80 Hence, most of the contraindications are 
expert opinions and not evidence-based. Earlier studies have shown increased rates of 
sICH in presence of frequent protocol violations, suggesting strict adherence to the 
guidelines in order to achieve best possible outcomes.81 Other studies have, on the 
other hand, shown that administration of tPA may be safe in the presence of certain 
contraindications. Hence, off-label thrombolysis has turned into a controversial topic.  
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Figure 1: Norwegian contraindications to ischemic stroke treatment with tPA per September 2014. 
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Thrombolysis and sICH 
SICH is the most feared complication of intravenous thrombolysis with tPA. 
Administration of tPA systematically alters hemostasis due to depletion of circulating 
fibrinogen, inactivation of coagulation factor V and VIII and impaired platelet 
function.68 This impairment, in combination with ischemic injury to the blood-brain 
barrier, can lead to cerebral hemorrhage and neurological deterioration. Prior 
thrombolytic trials have defined sICH differently, especially concerning grades of 
neurological deterioration (table 1). Depending on which definition applied, rates of 
sICH range from 1.7% (SITS-MOST) to 6.4% (NINDS) in thrombolysed stroke 
patients.69, 74  SICH following thrombolytic therapy is in general associated with poor 
outcome and high mortality rates. 82, 83 Clinical predictors for sICH include advanced 
age, increased blood pressure and serum glucose on admission, prior history of 
hypertension, high stroke severity, prolonged time from symptom onset to treatment 
and pre-stroke treatment with aspirin.84, 85   
 
Augmenting thrombolysis – body temperature 
Early recanalization has a substantial impact on outcome due to the salvage of 
penumbral tissue. Intravenous thrombolysis with tPA recanalizes approximately 
twice as many clots as spontaneous recanalization, yet less than half of all clots.60 Up 
to 2/3 of patients with large artery occlusions may not achieve recanalization and a 
substantial proportion of thrombolysed stroke patients therefore remain disabled or 
dead.86, 87 Endovascular intervention with intra-arterial thrombolysis or mechanical 
thrombectomy achieves higher recanalization rates, but not necessarily improved 
outcomes as compared to intravenous tPA alone.88-90 As intravenous thrombolysis 
continues as first-line treatment for acute ischemic stroke, factors promoting 
recanalization and improved outcomes in tPA treated stroke patients are of great 
importance.91  
Body temperature may represent one of these factors.  Low body temperature or 
hypothermia is generally considered a potent neuroprotectant and may decrease 
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cerebral damage during ischemia.92 Animal studies have shown increased numbers of 
surviving neurons after ischemia at lower temperatures and increased stroke volumes 
at higher temperatures.93-95 Hypothermia has proved effective reducing neurological 
deficits after cardiac arrest in clinical trials.96 The exact mechanisms of hypothermic 
neuroprotection is unknown, although the lower temperatures seem to mitigate 
neuronal damage at different levels in the ischemic cascade: prevention of blood-
brain-barrier disruption and subsequent edema formation, reduced excitotoxic 
neurotransmitter release, lower metabolic rate and prevention of free radical 
production after reperfusion.93, 97, 98   
 
Concordantly, higher body temperatures may result in unfavorable outcome after 
ischemic stroke, possibly due to increased metabolic demands and increased free 
radical production.99 Body temperature is frequently increased in stroke patients and 
this increase may in some cases be caused by infection. Studies have shown an 
association between increased body temperatures within 24 hours after stroke onset 
and poor prognosis.100-103 Most of these studies used temperature measurements up to 
6 hours after stroke onset. Normalization of body temperature after ischemic stroke is 
therefore recommended, although there is no direct evidence to support this sort of 
treatment. A review of prior randomized trials could not find evidence to support the 
use of pharmacological or physical strategies to reduce temperatures in stroke 
patients.92 A placebo-controlled trial reported no overall effect of paracetamol on 
outcome after ischemic stroke, although a post-hoc analysis showed an association 
between paracetamol administration and favorable outcome in patients with 
temperatures >37.0 ºC.104 
 
Body temperature may play a different role in association with thrombolytic 
treatment. In vitro studies have demonstrated decreased lytic efficacy of tPA at lower 
temperatures.105, 106 A study investigating the effect of hypothermia on clot lysis by 
tPA in human clot models showed no thrombolytic effect of tPA at 30º C as 
compared to controls without any thrombolytic agent.105 Mean fractional clot loss 
was lower at 30-36 ºC than at 37 ºC in the models exposed to tPA. In support of these 
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findings, another in vitro study showed decreased clot lysis at lower temperatures 
when tPA was added to clot suspensions. 106 Other studies have indicated a beneficial 
effect of higher temperatures on thrombolysis.107-109 Although not used anymore, 
fibrinolysis by streptokinase was increased at higher temperatures.107 Heated tPA 
resulted in faster clot lysis in patients with acute lower limb ischemia receiving 
catheter-directed thrombolytic treatment.108 A prior study from the Bergen 
NORSTROKE Registry demonstrated a beneficial effect of high body temperatures 
on admission in stroke patients treated with tPA, whereas lower temperature was 
associated with favorable outcome in acute stroke patients not treated with tPA.109 
The authors suggested that the clinical benefit of high body temperature on clot lysis 
outweighed the potential neuroprotective effect of lower body temperatures in the 
first hours of tPA treated stroke. This suggestion was, however, partially disproved in 
another analysis including >2000 tPA treated stroke patients from prior 
neuroprotection trials.110 Outcomes were improved across temperatures from 35.5º C 
– 37.5 ºC, but lost significance at temperatures <35.5 ºC and >37.5 ºC. However, 
point estimates suggested an increasing beneficial effect in temperatures rising from 
36.0 ºC to 37.5 ºC. In lack of new evidence, a beneficial effect of higher body 
temperatures on tPA treated stroke patients remains uncertain.  
 
Other factors influencing thrombolysis 
Other factors may also influence the rate of clot lysis and recanalization with tPA. 
Recanalization after 24 hours occurs spontaneously in approximately one quarter of 
all patients whereas the rate increases to ≈ 46% if treated with intravenous 
thrombolysis.60 Recanalization with tPA seems to depend on vessel site and clot 
burden with lower recanalization rates in larger arteries.111 Doppler controlled studies 
have shown a recanalization rate of 44%, 29% and 10% at 2 hours in tPA treated 
patients with distal middle cerebral artery occlusion, proximal middle cerebral artery 
occlusion and internal carotid artery occlusion, respectively.111 This is likely 
explained by the increased clot volume in the more proximal sites, making it difficult 
for the administered tPA to penetrate the clot and achieve recanalization. Clot 
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etiology also has an impact on recanalization rates with tPA. Cardioembolic clots are 
more likely to be recanalized with intravenous thrombolysis as compared to clots of 
similar size originated elsewhere.67 This may be explained by the high amount of 
fibrin in cardioembolic clots, which make these clots more suitable for fibrinolytic 
treatment.  
Clot composition and the effect of tPA on clot lysis may also be influenced by 
external factors, such as cigarette smoking. Smoking is a well-known risk factor for 
cardiovascular events, such as myocardial infarction or ischemic stroke. This has 
partially been attributed to increased platelet activation and higher fibrin 
concentrations in smokers, causing the blood to become hypercoagulable.112, 113 
Smokers are therefore at higher risk of clot formation causing ischemic stroke. When 
stroke occurs, the clot may be thrombolysed faster with tPA due to the increased 
proportion of clot fibrin. This could lead to more rapid recanalization and better 
outcomes. In support of this theory, studies have shown improved myocardial 
perfusion and lower mortality rates in smoking patients with myocardial infarction 
treated with thrombolysis.114, 115 This smoking-thrombolysis paradox has also been 
reported in stroke patients treated with tPA where smoking resulted in improved rates 
of recanalization and better prognosis.116, 117 Other stroke studies have, however, 
failed to find these associations and attributed the beneficial effect of smoking to the 
low clinical risk profiles of these patients.118-120  
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Aims of the thesis 
1. To assess whether an increased use of DWI leads to a decreased proportion of 
tissue-based TIA diagnosis, the frequency of DWI lesions in patients with 
transient ischemic symptoms <24 hours and clinical characteristics in these 
patients as compared to those without DWI lesions. We hypothesized that an 
increased use of DWI would lead to a decreased proportion of TIA, a high 
proportion of DWI lesions in patients with transient ischemic symptoms <24 
hours and that patients with DWI lesions would differ from those without DWI 
lesions regarding extent of performed diagnostic investigations and clinical 
characteristics. This hypothesis is discussed in paper I. 
2. To assess whether location of DWI lesions in stroke patients with transient 
symptoms <24 hours differs from the location in those with persistent 
symptoms. We hypothesized a higher proportion of cortical DWI lesions in 
patients with transient symptoms. This hypothesis is discussed in paper II. 
3.  To assess frequency, safety and outcome of off-label stroke treatment with 
tPA. We hypothesized a high frequency of off-label treatment and no 
independent association between off-label treatment and rates of sICH or 
unfavorable outcome. This hypothesis is discussed in paper III.  
4. To assess the relationship between body temperature and major neurological 
improvement in patients with cerebral ischemia treated with tPA. We 
hypothesized an independent association between higher body temperature and 
major neurological improvement. This hypothesis is discussed in paper IV.  
5. To assess the relationship between smoking and outcome in acute ischemic 
stroke treated and not treated with tPA. We hypothesized an association 
between smoking and favorable outcome in stroke patients treated with tPA 
and no such association in acute stroke patients not treated with tPA. This 
hypothesis is discussed in paper V.   
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Material and methods 
The Bergen NORSTROKE Study 
Data for all papers were obtained from the Bergen NORSTROKE Study. The Bergen 
NORSTROKE Study prospectively registers patients admitted to the Department of 
Neurology, Haukeland University Hospital with ischemic stroke, TIA or ICH. The 
stroke centre at Haukeland University Hospital has a catchment area of 
approximately 150.000 inhabitants. In addition, patients with stroke aged <60 years 
from a neighbouring area (approximately 120.000 inhabitants) are admitted. The 
Bergen NORSTROKE Study started inclusion of patients in February 2006 and is 
still ongoing. Patient demography, prior medical history, clinical data, short-term 
outcomes and results from examinations, including radiological, cardiological and 
neurosonological findings are registered. Informed consent is obtained from the 
patient or legal representative before inclusion. The study has been approved by the 
regional ethics committee.  
 
General management  
Patients may be admitted directly to the hospital without prior medical examination if 
symptoms include persistent or transient acute neurological deficits. If symptoms 
started within 6 hours, patients are brought in by an emergency ambulance. Patients 
are clinically examined in the emergency department by a junior neurologist. The 
examination includes scoring with NIHSS and registration of physiological 
parameters, such as blood pressure and body temperature. From 2006 to 2009, body 
temperature was measured by an infrared tympanic device (LightTouch-LTX; 
Exergen Corp, Watertown, MA, USA). Since 2009, body temperature has been 
measured by using a temporal artery thermometer (Exergen Temporal Scanner; 
Exergen Corp). Blood samples, including haemoglobin, leucocytes, glucose, CRP, d-
dimer and fibrinogen are obtained on admission.  
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After clinical examination, patients routinely undergo non-contrast CT. This is 
performed as quickly as possible if patients are candidates for recanalizing treatment.  
These patients are also routinely examined with CTA. Thrombolytic treatment is 
initiated in the CT lab and continued as the patient is transported to the stroke unit. 
Since 2008, patients with major occlusions have been offered treatment with 
endovascular intervention in addition to intravenous thrombolysis.  
 
After arrival at the stroke unit, patients are monitored with frequent observations of 
physiological parameters and NIHSS scoring by a stroke nurse. Patients are regularly 
examined by a neurologist the next day after admission. Unless any contraindications 
are present, MRI and MRA are routinely performed on the day after admission in 
patients with suspected ischemic stroke or TIA.  MRI capacity was, however, limited 
during the first years of the NORSTROKE Study. Not all patients with suspected TIA 
were therefore examined with DWI during this time period. DWI is performed as part 
of a routine MRI protocol for stroke patients on 1.5 Tesla Siemens Magnetom 
(Symphony, Erlangen, Germany). The DWI sequence is ep2d_diff:3scan_trace, with 
the following specification of parameters: field of view (FOV) 230 mm, slice 
thickness 5 mm, TR 3200 ms, TE 94 ms. Additional sequences were t2_flair_tra and 
ep2e_diff_3scan_trace_ADC. Duplex ultrasound examination of the extracranial 
arteries is regularly performed within the day after admission. If clinical history and 
findings indicate cardioembolic etiology, patients undergo echocardiography and 24-
hour-Holter monitoring. Patients are mobilized early and referred to a multi-
professional rehabilitation team as appropriate.  
 
NORSTROKE Study registration 
Data for the NORSTROKE Study is routinely registered on the day after admission 
by a stroke neurologist based on a predefined questionnaire. Patients with stroke 
mimics are not included in the NORSTROKE Study. Patient’s age, sex and time of 
symptom onset are registered in addition to pre-morbid dependency and prior medical 
diseases. Pre-morbid dependency is based on premorbid residency and need for 
assistance. Prior medical diseases include: hypertension, considered present if 
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diagnosed by a physician before stroke onset; diabetes mellitus, present if glucose 
lowering diet or medication has been initiated before admission; atrial fibrillation, 
present if confirmed by ECG at any time prior to admission or during hospital stay. 
Registration of prior myocardial infarction, stroke or TIA is based on information 
from the patient, partner or relatives of the patient or medical journal. Smoking habits 
are separated into the following categories: current smoking, previous smoking and 
no smoking. Current smoking is defined as smoking at least one cigarette per day. 
Previous smoking requires cease of smoking at least one year before stroke onset. No 
smoking is considered present if the patient has never smoked. Premorbid medication 
is also registered in the NORSTROKE Study.  
 
Clinical data on admission is registered and includes NIHSS score, blood pressure, 
pulse frequency and body temperature. Blood samples on admission, including 
haemoglobin, leucocytes, glucose, CRP, d-dimer and fibrinogen are registered. Based 
on type of neurological deficits on admission, patients are categorized into different 
stroke syndromes based on the OCSP classification. Stroke etiology is classified by 
the TOAST classification. This is based on clinical examination, neuroimaging 
results including ultrasound of extracranial arteries and cardiac examination. 
Registration of OCSP and TOAST has been performed by the same stroke 
neurologist during the entire study period (Halvor Næss).  
 
Use and results of diagnostic work-up during the hospital stay, including CT and MRI 
are registered. If present, DWI lesions are classified into different groups depending 
on location; Cortical, lesions confined to the supratentorial cortex; mixed cortical-
subcortical, lesions located both in the supratentorial cortex and subcortex; large 
subcortical, lesions located in the basal ganglia, internal capsule or corona radiate 
with a diameter ≥15 mm; lacunar, lesions located in the basal ganglia, internal 
capsule or corona radiate with a diameter <15 mm; cerebellar, lesions confined to the 
cerebellum; brain stem, lesions confined to the brain stem; multiple locations, lesions 
in more than one of the above defined areas (table 2). SICH on CT or MRI is defined 
as any intracerebral hemorrhage with any decline in neurological status. All MRI and 
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CT scans were reviewed and classified by the same stroke neurologist during the 
entire study period (Halvor Næss).  
Table 2: Location of DWI lesions in the NORSTROKE Study 
 
 
 
 
 
 
 
 
NIHSS scores performed by stroke nurses or neurologists are registered along with 
the respective time points of the examinations during the hospital stay. NIHSS scores 
after 24 hours and 7 days (or at discharge, if discharged earlier) are used to assess 
clinical development in paper IV and III, respectively.  In paper IV, major 
neurological improvement is defined as ≥8 point improvement in NIHSS score at 24 
hours as compared to NIHSS score on admission. In paper III, NIHSS scores at day 7 
or at discharge is compared to the NIHSS score on admission. Clinical improvement 
is here defined as an improvement of 4 points or more or NIHSS=0 at discharge. 
Clinical worsening is defined as a worsening of 4 points or more. Patients are 
considered clinical stable if they experience neither improvement nor worsening.  All 
patients are scored with mRS on day 7 or at discharge, if discharged earlier. Mortality 
rates 30 days after discharge are extracted from the Norwegian Death Registry.  
 
Statistics 
Student`s t-test, Wilcoxon rank-sum test and Analysis of variance (ANOVA) are used 
Variable name Corresponding areas of DWI lesion(s)  
Cortical Supratentorial cortex 
Mixed cortical-subcortical Supratentorial cortex and subcortex 
Large subcortical Basal ganglia, internal capsule or corona radiate ≥15 
mm 
Lacunar Basal ganglia, internal capsule or corona radiate <15 
mm 
Cerebellar Cerebellum 
Brain stem Brain stem 
Multiple More than one of the above defined areas 
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as appropriate for continuous variables. Fischer`s exact test and chi-square test are 
used for categorical variables. Logistic regression analyses are performed as 
appropriate by using stepwise backward elimination. Analyses are performed with the 
software “STATA/SE 11.0 for Windows” (Stata Corp, College station, TX, USA).  
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Summary of papers 
Paper I: Clinical implications of increased use of MRI in TIA. Kvistad CE, 
Thomassen L, Waje-Andreassen U, Moen G, Logallo N, Naess H. Acta 
Neurol Scand 2013 Jul;128(1): 32-8. 
 
Background: DWI is highly sensitive in detecting ischemic brain injury. With a new 
tissue-based TIA definition, we investigated whether an increased use of DWI 
resulted in a decrease in TIA diagnosis as compared to ischemic stroke. We also 
aimed to assess proportion and clinical characteristics of DWI positive patients with 
transient ischemic symptoms <24 hours as compared to DWI negative TIA patients.  
Methods: Patients admitted with ischemic stroke or TIA were prospectively 
registered from 2006 to 2011 and the use of DWI annually recorded. Clinical 
characteristics, diagnostic work-up and etiology were registered in DWI positive 
patients with transient ischemic symptoms <24 hours and compared to those without 
DWI lesions. 
Results: Use of DWI increased from 65% in 2006-2008 to 89% in 2009-2011 
(p<0.001) and the proportion of TIA decreased from 12.2% to 8.3% (p=0.002). A 
total of 236 patients were included with transient ischemic symptoms, of which 113 
patients (47.9%) had DWI lesions. Use of echocardiography (p<0.001) and 24-h 
Holter monitoring (p<0.001) was more frequent in DWI positive patients as 
compared to DWI negative patients. Lower age (p<0.001) and prior myocardial 
infarction (p=0.029) were independently associated with DWI lesions in patients with 
transient ischemic symptoms. There was a non-significant trend of prior paroxysmal 
atrial fibrillation being associated with DWI lesions (p=0.089).  
Conclusion: An increased use of DWI resulted in a decrease in proportion of TIA. 
Although patients with transient ischemic symptoms and DWI lesions had a more 
extensive cardiac work-up, our results indicate an association between presence of 
DWI lesions and cardioembolic stroke mechanism.  
  
36 
36 
Paper II: Diffusion-weighted lesions in stroke patients with transient 
symptoms – where are they located? Kvistad CE, Logallo N, Moen G, 
Thomassen L, Waje-Andreassen U, Naess H. Cerebrovasc Dis. 2014;38: 
219-225. 
Background: A number of patients with transient ischemic symptoms <24 hours 
have DWI lesions and are diagnosed as ischemic stroke and not TIA with the new 
tissue-based TIA definition. These patients experience complete neurological 
recovery within 24 hours, which may suggest successful vessel recanalization. We 
sought to see whether DWI location differed in stroke patients with transient 
symptoms hours as compared to those with persistent symptoms and hypothesized a 
higher proportion of cortical DWI lesions in patients with transient symptoms due to 
a possibly increased rate of recanalization in this group.  
Methods: Patients admitted between 2006 and 2013 with acute ischemic stroke 
examined with DWI were included and classified according to DWI location into 
cortical, mixed cortical-subcortical, large subcortical, lacunar, cerebellar, brain stem 
or multiple locations in more than one of the above defined areas. Location of DWI 
lesions in patients with transient symptoms was compared to DWI location in stroke 
patients with persistent symptoms.  
Results: A total of 972 patients with acute ischemic stroke were included, of which 
142 (14.6%) patients had transient symptoms <24 hours. A larger proportion of 
patients with transient symptoms had cortical DWI lesions, whereas mixed cortical-
subcortical location and lesions with multiple locations were more frequent in 
patients with persistent symptoms. Cortical DWI location was independently 
associated with transient symptoms when adjusted for confounders (OR 1.89, 
p=0.001).  
Conclusions: Patients with transient symptoms <24 hours had more frequently 
cortical DWI lesions. This may be explained by a high rate of successful 
recanalization, resulting in upstream displacement of particles after recanalization and 
subsequent distal cortical DWI lesions. 
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Paper III: Safety of off-label stroke treatment with tissue plasminogen 
activator. Kvistad CE, Logallo N, Thomassen L, Waje-Andreassen U, 
Brøgger J, Naess H. Acta Neurol Scand. 2013 Jul;128(1): 48-53. 
Background: Recanalizing treatment with tPA is limited to a small group of stroke 
patients due to a number of contraindications. Most of these contraindications are 
based only on expert opinion. We aimed to assess frequency, safety and outcome in 
patients treated off-label with tPA. We hypothesized a high proportion of patients 
being treated off-label with tPA and no independent association between off-label 
tPA treatment and sICH or unfavorable outcome. 
Methods: Patients with ischemic stroke treated with tPA during 2006-2011 were 
prospectively registered. Rates of sICH, clinical improvement, short-term outcome 
and 30-day mortality were assessed in patients with contraindications to tPA and 
compared to the rates in thrombolysed patients without any contraindications or 
patients who had compatible contraindications and did not receive tPA.  
Results: A total of 135 patients (50.9%) were treated off-label with tPA and 130 
patients (49.1%) were treated without any contraindications. There were 134 patients 
with contraindications not treated with tPA. Rates of sICH and clinical improvement 
were similar in patients treated with tPA with or without contraindications, whereas 
short-term outcome was worse and mortality rates higher in tPA-treated patients with 
contraindications as compared to those without. Off-label treatment with tPA was not 
associated with unfavorable outcome or death when adjusted for age, sex and stroke 
severity on admission. A larger proportion of patients with contraindications treated 
with tPA experienced clinical improvement as compared to those with 
contraindications not treated with tPA, although outcome and mortality rates were 
similar.   
Conclusions: Presence of contraindications to tPA did not independently predict 
unfavorable outcome or death. Off-label thrombolytic treatment may be safe and 
efficient in acute ischemic stroke.  
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Paper IV: Body temperature and major neurological improvement in 
tPA-treated stroke patients. Kvistad CE, Thomassen L, Waje-
Andreassen U, Logallo N, Naess H. Acta Neurol Scand. 2014 May;129(5): 
325-9. 
Background: In thrombolytic stroke treatment a major goal is recanalization, of 
which major neurological improvement within 24 hours (MNI) represents a useful 
surrogate marker. Studies have suggested an increased thrombolytic effect of tPA at 
higher temperatures. We hypothesized an independent association between MNI and 
higher admission body temperatures in patients with acute cerebral ischemia treated 
with tPA.  
Methods: Admission body temperatures of patients with cerebral ischemia treated 
with tPA between 2006 to 2012 were registered. MNI was defined as ≥8 point 
improvement in NIHSS score at 24 hours as compared to NIHSS score on admission. 
No significant improvement (no-MNI) was defined by either a worsening in NIHSS 
score or an improvement of ≤2 points at 24 hours in patients with an admission 
NIHSS score of ≥8 points. Patients with MNI and no-MNI treated with tPA were 
included. 
Results: A total of 347 patients were treated with tPA, of which 32 patients (9.2%) 
had MNI and 56 (16.1%) no-MNI. Mean admission body temperature was higher in 
patients with MNI as compared to those with no-MNI (36.7 ºC vs. 36.3 ºC, p=0.004). 
Higher body temperature was independently associated with MNI when adjusted for 
confounders (OR 5.16, p=0.003).  
Conclusions: Higher body temperature was independently associated with MNI in 
patients with acute cerebral ischemia treated with tPA. This may suggest a beneficial 
effect of higher body temperature on clot lysis and recanalization.  
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Paper V: Is smoking associated with favorable outcome in tPA-treated 
stroke patients? Kvistad CE, Oeygarden H, Logallo L, Waje-Andreassen 
U, Naess H. Acta Neurol Scand. 2014 Nov;130(5): 299-304. 
Background: Smoking may lead to improved outcomes after thrombolytic treatment 
for myocardial infarction. Some studies have shown higher recanalization rates in 
smoking stroke patients as compared to non-smokers, although other studies have 
shown different results. We hypothesized an association between smoking and 
favorable short-term outcome in stroke patients treated with tPA and no such 
association in acute stroke patients not treated with tPA, suggesting a beneficial effect 
of smoking on thrombolysis with tPA.  
Methods: Smoking habits in acute stroke patients admitted between 2006 and 2013 
were registered and categorized into three different groups: current smoking, previous 
smoking and no smoking. Associations between smoking habits and short-term 
outcomes were assessed in stroke patients treated with tPA and stroke patients 
admitted within 6 hours after stroke onset and not treated with tPA.  
Results: A total of 399 patients were treated with tPA, of which 94 were current 
smokers, 148 previous smokers and 157 non-smokers, whereas 424 patients were not 
treated with tPA, of which 90 were current smokers, 164 previous smokers and 170 
non-smokers. There was an independent association between current smoking and 
favorable outcome in patients treated with tPA (OR 2.08, p=0.025), but not in 
patients not treated with tPA (OR 1.26, p=0.472).  
Conclusion: Current smoking was independently associated with favorable outcome 
in tPA treated stroke patients, but not in acute stroke patients not treated with tPA. 
These findings are in support of a more effective thrombolysis with tPA in smokers. 
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Discussion 
TIA – The issue is tissue 
With a tissue-based TIA definition, rates of TIA and ischemic stroke will depend on 
brain imaging availability and utility, especially on DWI considering its high 
sensitivity to ischemic injury. Our study confirms the strong relationship between use 
of DWI in patients with possible transient ischemic attack and rates of TIA using a 
tissue-based definition (figure 2) (paper I). This relationship occurs because a 
considerable number of patients with an apparent TIA have ischemic lesions on DWI. 
With a tissue-based TIA definition, these patients are characterized as ischemic stroke 
and not as TIA. In our population, approximately half of the patients with transient 
symptoms examined with DWI had ischemic lesions. This number is similar to that 
found in previous studies, although a recent meta-analysis pointed at a considerable 
variability of this proportion across different studies.10, 11, 121, 122 
There is more than one explanation why some patients with transient symptoms 
demonstrate ischemic lesions on DWI while others do not. One explanation may be 
linked to recanalization. Spontaneous recanalization could lead to absence of 
ischemic injury and DWI lesions if full reperfusion is achieved within short enough 
time. In patients with transient symptoms and DWI lesions, a relatively late or 
incomplete recanalization may fail to prevent ischemic damage, yet prove sufficient 
to facilitate reperfusion and reverse stroke symptoms. The clots responsible for the 
DWI lesions could, in other words, be less inclined to undergo spontaneous 
recanalization as compared to the clots in patients without DWI lesions. This 
suggestion may be supported by our findings, which pointed at an independent 
association between cardioembolic stroke etiology and presence of DWI lesions. 
Cardioembolic clots are larger in size as compared to clots of other etiological origin 
and have been associated with more severe strokes.123 As a consequence, these clots 
may less prone to recanalize spontaneously, resulting in higher chances of leaving 
ischemic footprints on DWI.   
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Figure 2: Proportion of MRI scans in patients with transient symptoms <24 h and proportion of TIA diagnosis 
as compared to ischemic stroke in percentage.  
 
The absence of DWI lesions in some patients with cerebral ischemia may also be 
explained by collateral circulation. Reduced perfusion due to an occluding clot can 
promote blood flow through collateral vessels. Primary collateral pathways are 
represented by the arteries of the circle of Willis, while secondary pathways include 
the leptomeningeal vessels.65 Patients with transient ischemia without DWI lesions 
may have benefitted from more potent collateral anastomoses averting ischemic 
damage whereas the robustness of collateral vessels in DWI positive patients proved 
insufficient to prevent ischemic damage. The theory of collateral circulation 
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preventing ischemic damage on DWI is speculative since data of collateral circulation 
was not registered.  
 
Stroke mimics could offer another explanation to the differences between DWI 
positive and negative patients with transient stroke symptoms. It is sometimes 
difficult to distinguish between vascular and non-vascular etiologies in patients 
presenting with transient stroke symptoms. A positive DWI makes this decision 
easier. In these patients, the ischemic origin of the symptoms is more or less clear. It 
may be more difficult to separate a vascular event from disorders mimicking vascular 
events in patients with a negative DWI. Nevertheless, the gold standard of TIA 
remains the judgment of a vascular neurologist.28 Stroke mimics are not registered in 
the NORSTROKE Study, yet a number of patients with stroke mimics labeled as TIA 
may have been difficult to avoid. And vica-versa, some patients with true TIA may 
have been diagnosed as stroke mimic with a negative DWI. These points should also 
be taken into account when studying the differences between DWI positive and 
negative patients with an apparent TIA. The younger age of patients with DWI 
lesions could be explained by this. Because age itself represents an important risk 
factor for vascular pathology, the clinician may have tended to label transient 
symptoms as TIA in older patients with negative DWI, but suspected stroke mimics 
in younger patients with negative DWI. This may have contributed to the higher age 
in DWI negative patients with transient stroke symptoms as compared to those with 
positive DWI. The relationship between prior myocardial infarction and presence of 
DWI lesions could also be explained by a dilution of the true ischemic events in the 
DWI negative group with stroke mimics. A history of coronary heart disease is a risk 
factor for ischemic cerebrovascular events but not necessarily for stroke mimic 
events.43, 124 125All patients with DWI lesions had an ischemic event while some 
patients without DWI lesions could actually have had stroke mimics although labeled 
as true ischemic events. This could have led to a higher rate of causal ischemic stroke 
risk factors, such as ischemic heart disease, in the DWI positive group while the 
group of DWI negative patients had a lower rate of ischemic heart disease because 
this group in reality consisted of a proportion of stroke mimics where ischemic heart 
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disease is less prevalent. These points draw attention to the difficulty of comparing 
DWI positive and negative patients because a true vascular diagnosis is more certain 
in those with DWI lesions. The difficult TIA diagnosis highlights the importance of 
performing MR-DWI in these patients. 
 
The importance of DWI in TIA 
In TIA and ischemic stroke, therapeutic decisions depend on an accurate diagnosis 
and etiological classification. In this context, stroke mimics such as migraine or 
epileptic seizures are important differential diagnoses to TIA and minor strokes. Up 
to half of all TIA-referrals to stroke centers are stroke mimics.126-128 As 
approximately 20% suffer an ischemic stroke within 3 months after a TIA, 
misclassifying TIA as stroke mimic could have dramatic consequences. Unlike TIA, 
stroke mimics is associated with an excellent cardiovascular prognosis.129 To 
diagnose a stroke mimic as TIA would therefore also be a mistake with negative 
implications such as erroneous initiation of secondary cardiovascular prevention, 
incorrect patient information of long-term prognosis and delay of appropriate 
assessment of the true illness, which caused the apparent TIA. Magnetic resonance 
with DWI is very sensitive to even small areas of ischemic injury.130 The importance 
of differentiating between TIA and stroke mimics is an important argument for DWI 
assessment in all patients with an apparent TIA.  
 
DWI also has other values in TIA assessment, such as the recognition of ischemic 
patterns. DWI lesions in different vascular territories point at a cardiovascular cause 
of the ischemic event, while small lesions in the basal ganglia suggest lacunar stroke. 
This different display of DWI lesions may provide important information to stroke 
etiology and thereby ensure right treatment to the right group of patients. In addition, 
presence of DWI lesions also provides prognostic information. Studies have reported 
of an increased risk of subsequent ischemic stroke in patients with transient ischemic 
symptoms and DWI lesions as compared to those without DWI lesions. 13, 131, 132 
  
44 
44 
These prognostic differences also support the concept of a tissue-based TIA 
definition.  
 
Location of DWI lesions in transient and permanent symptoms 
Patients with DWI lesions due to cerebral ischemia may recover completely within 
short time or suffer more persistent neurological deficits. Previous studies have 
shown that DWI lesions in patients with transient symptoms are smaller as compared 
to those with persisting symptoms, yet few studies have looked into if DWI lesions 
are located differently in these two groups of patients.7, 12 In our study, we found an 
independent association between cortical DWI location and transient symptoms with 
duration less than 24 hours (paper II). Indirectly, these findings are in concordance 
with other studies, which have reported a relatively high frequency of cortical 
cerebral dysfunction in patients with transient symptoms and DWI lesions, such 
aphasia.14, 93, 122 A possible explanation may be linked to recanalization. Rapid 
neurological recovery, either spontaneous or mediated through thrombolytic 
treatment, is likely to be the result of recanalization and reperfusion. In the process of 
recanalization, the clot breaks up into fragments. These fragments are transported 
with the restored anterograde blood flow to distal cortical regions. Here, the 
fragments occlude smaller, cortical vessels. These occlusions could be large enough 
to cause cortical DWI lesions, but too small to produce persistent neurological 
deficits.  
 
In opposition to this theory, only 43% of patients with transient symptoms and an 
occlusion on admission CTA had achieved complete recanalization on MRA the next 
day. Although only 14 patients were included in this specific analysis, the relatively 
low rate of recanalization in this group could be interpreted as a challenge to the link 
between recanalization and reversibility of neurological symptoms. However, also 
partial recanalization may lead to sufficient reperfusion and clinical improvement. 
Due to the small number of patients with an occlusion on admission CTA, only 
complete recanalization was registered in this study. 
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Neurological deficits caused by ischemia vary depending on which area the ischemia 
affects. Smaller subcortical lesions in the basal ganglia or brain stem may cause 
severe neurological symptoms due to injury of a large number of axons concentrated 
in white matter tracts.133 Lesions of similar size located in the cortex could result in 
milder and less persistent symptoms due to the wider distribution of cortical functions 
in this area.134 This could also offer a potential explanation of our results. In addition, 
studies have shown an increased perilesional reorganization and plasticity after 
cortical lesions, resulting in improved recovery.135 However, our study showed a high 
rate of cortical DWI lesions in patients with reversible symptoms at 24 hours, a time 
frame probably too short for plasticity to take place.  
Another explanation may be based on lesions size. Studies have shown a correlation 
between DWI lesion volume and neurological development and outcome134, 136, 
although other studies have come to different conclusions.137  The association 
between transient symptoms and cortical DWI lesions could thus be based on the 
smaller size of these lesions as compared to those located in other regions. The lack 
of DWI volume measurement is a limitation in our study. However, previous studies 
have shown an association between size of DWI lesions and stroke severity on 
admission.134 We adjusted for stroke severity using NIHSS score on admission in our 
analyses and thereby partly compensated for the lack of volume data. 
 
TIA- a dying breed?  
With a tissue-based distinction between TIA and ischemic stroke, the diagnosis of 
TIA is dependent on a credible patient history of vascular origin and absence of 
ischemic damage on imaging. TIA will only be evident in patients where severity and 
duration of ischemia was sufficient to cause symptoms, but no infarcted tissue. As 
sensitivity of detecting ischemic injury increases, rates of TIA are thus bound to 
decrease in favor of ischemic stroke. In this context one might question if all DWI 
lesions should be considered as representing infarction. Infarction implies permanent 
injury, yet some studies have shown that DWI lesions can be reversible.19 In spite of 
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this, a recent large, prospective study reported that DWI reversal is uncommon in 
patients with TIA or minor stroke and occurred only in 5.7% of the patients after 3 
months in follow-up MR imaging with FLAIR (fluid-attenuated inversion recovery). 
138 In addition, not all DWI lesions are necessarily of ischemic origin. Studies have 
shown DWI lesions in patients with different conditions, such as transient global 
amnesia, epileptic seizures and multiple sclerosis.139-141 The ischemic origin of a DWI 
lesion in a patient with transient symptoms should thus not always be taken for 
granted.  
A different ischemic stroke population is another consequence of a tissue-based TIA 
definition. A large part of yesterday’s patients with TIA are now registered as 
ischemic stroke due to DWI lesions on MRI. Because prognosis is more favorable in 
DWI positive patients who already have recovered from their symptoms, a general 
shift towards a better prognosis after ischemic stroke will be the consequence. This 
will, however, depend on local use of MRI and DWI, especially in patients with 
possible TIA. Methodological consequences and challenges in future stroke trials will 
also emerge. Modified Rankin scale score after 90 days have been used as primary 
outcome in major stroke trials for several years. A score of 0-1 or 0-2 have been 
considered as favorable outcome. This score may prove too inaccurate when patients 
previously diagnosed with TIA now are included in these trials as ischemic stroke 
patients. An increased number of patients will have to be included in order to achieve 
an acceptable power. With tissue-based TIA and stroke definitions, perhaps the time 
has come to replace the traditional definitions of outcome with other outcome 
parameters or methods.  
 
Thrombolytic treatment 
The failure of spontaneous recovery of ischemic neurological deficits may be caused 
by persistent occlusion. This supposition is the rationale for thrombolytic treatment in 
patients admitted with acute ischemic stroke symptoms. The beneficial effect of 
thrombolytic therapy is based on the augmentation of recanalization and reperfusion. 
In order to achieve clinical improvement after recanalization, the recanalization must 
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be achieved while there still is salvageable tissue. The clinical effect of thrombolytic 
treatment is in other words highly time dependent, which is demonstrated in figure 3.  
 
Figure 3: The effect of tPA decreases with time 
 
Adopted from Hacke et al. Lancet 2004: 363: 768-74. 
 
This means that thrombolysis should be administered to eligible patients as soon as 
possible after hospital arrival. Under these circumstances the clinician has to balance 
the running time, with its potential loss of neuronal tissue, against the assessment of 
factors that may contradict thrombolytic treatment. Such factors include (a) 
uncertainty whether the symptoms are of ischemic origin, (b) if the symptoms could 
improve spontaneously without thrombolytic treatment or (c) if one or more 
contraindications to tPA are present. This assessment is important because (a) there is 
no benefit in treating a patient with stroke mimics or (b) a patient without stroke 
symptoms and (c) treating a patient with contraindications to tPA could increase the 
risk of sICH, which often outweighs the beneficial clinical effect of early 
recanalization.  
In cases of (a), increasing evidence suggest that thrombolytic treatment in stroke 
mimics is safe. Across different studies, rates of stroke mimics erroneously receiving 
OR 
Min 
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thrombolysis varies between 2.8% to 21%, yet none of these patients suffered from 
sICH.125, 142, 143 These findings indicate that thrombolytic treatment does not alter the 
frequently favorable natural prognosis in stroke mimics. Consequently, the general 
benefit of tPA is not reduced by the potential harm of thrombolysing patients with 
stroke mimics.  
Clinicians also do not wish to treat patients with transient ischemic attacks where 
recanalization already has occurred and symptoms have reversed (b). A recent 
Norwegian study showed that thrombolysis was not administered in more than one 
third of admitted patients with acute ischemic stroke due to mild or rapidly improving 
symptoms.144 The problem with rapidly reversing symptoms is that they may not 
improve completely. Although recanalization has occurred, fragments from the 
original clot may re-occlude distal arteries, causing remaining neurological deficits. It 
is also possible that a robust collateral circulation may temporarily compensate for an 
occlusion. Clinical deficits can be vague and too obscure to be detected in the setting 
of a pragmatic neurological examination in the emergency ward. Such deficits 
include neglect, dyscalculia, apraxia, gait disturbances and anosognosia. Symptoms 
not sufficiently apprehended by the NIHSS scale, such as deficits from the right 
hemisphere are also easily missed.145, 146 Studies show that treating patients with 
minor stroke symptoms or regressing stroke symptoms may be safe and efficient.147-
149 These findings support an aggressive approach when it comes to patients with 
improving stroke symptoms and thrombolysis.  
Another factor, and perhaps the most important one, is the presence of 
contraindications to trombolytic treatment (c). These are numerous and the systematic 
setup of contraindications listed in the national guidelines is appreciated by the 
clinician in the demanding setting of an acute stroke.78 A number of contraindications 
to tPA are listed in these national guidelines, which may exclude a considerable 
proportion of patients from thrombolysis and thereby limit the general availability of 
this treatment. The listed contraindications are in general derived from earlier 
thrombolytic trials where patients with a presumed risk of cerebral hemorrhage or 
increased risk of unfavorable treatment results were excluded from participation. The 
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strict compliance of these guidelines may result in the exclusion of patients who 
potentially might benefit from thrombolytic treatment.  
Our department has long experience in the administration of thrombolytic treatment 
and was the first center in Norway to routinely treat ischemic stroke patients with 
tPA. This experience could have resulted in a relatively liberal view on a number of 
the contraindications listed in the national guidelines. This is supported by our 
findings, which showed that approximately half of the patients treated with tPA had 
one or more contraindications to tPA (paper III). There was a similar number of 
patients with contraindications to tPA who did not receive thrombolytic treatment. 
The distribution of contraindications in patients treated and not treated with tPA are 
illustrated in figure 4.  
Figure 4: Distribution of contraindications in patients treated (off-label) and not treated with tPA (off-label no 
tPA). 
 
There was no significantly increased risk of sICH in patients treated off-label with 
tPA as compared to those treated without any of the listed contraindications. 
Although rates of unfavorable outcome and mortality were higher in patients treated 
off-label, the presence of contraindications to tPA was not associated with worse 
prognosis when adjusted for confounders, such as age, sex and stroke severity on 
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admission. This points at a different cause for the unfavorable prognosis in patients 
treated off-label rather than the thrombolytic treatment itself. When off-label patients 
were compared to those who had contraindications and were not treated with tPA, 
there was a trend towards a beneficial effect of thrombolytic treatment. In addition, a 
higher proportion of patients treated off-label experienced neurological improvement 
during the hospital stay as compared to those who had contraindications and were not 
treated with tPA (figure 5).  
Figure 5: Distribution of clinical improvement, stability or worsening between patients with contraindications 
treated with tPA (off-label), patients without contraindications  treated with tPA (on-label) and patients with 
contraindications not treated with tPA (off-label no tPA).  
 
These results must, however, be interpreted with caution. The non-randomized, 
retrospective design of the study makes it difficult to directly compare these groups 
of patients. The question to treat or not to treat with tPA is left to the clinical 
judgment of the clinician at charge. The decision is based on several factors such as 
prior diseases, clinical status and development and co-concomitant patient 
medication. The present contraindications in some patients not treated with tPA may 
not have been the direct cause of withholding thrombolytic treatment, rather an 
indirect cause tipping the balance in favor of no thrombolysis.  A randomized, 
  
51 
51 
placebo-controlled study could have eliminated this problem. Such a study may 
however be difficult to perform due to ethical issues.  
Our results are in conformity with other similar studies looking either at separate or 
multiple contraindications to tPA (table 3). 
Table 3: Studies of stroke patients treated off-label with tPA using similar contraindications as in our study in 
addition to minor stroke symptoms.     
Authors Contra- 
indications 
Inclusion 
period 
N  
(off-label) 
Conclusion Ref 
Tanne et al.  Age ≥80  1995-1997 30 No evidence to support 
withholding tPA in patients 
aged ≥80 
150 
Engelter et 
al.  
Age ≥80  1998-2003 38 Rates of favorable outcome 
and sICH similar in patients 
≥80 and <80 
151 
Berrouschot 
et al. 
Age >80 2000-2004 38 No increase in sICH, but 
outcome worse as compared 
to younger patients 
152 
Sylaja et al.  Age ≥80  2002-2005 270 No increased risk of sICH in 
patients aged ≥80  
153 
Ford et al.  Age >80  2002-2008 1831 Selected patients >80 years 
appropriate candidates for 
tPA. Poorer prognosis due to 
natural history 
154 
Mishra et al.  Age >80  2002-2009 3472 Increasing age associated 
with worse prognosis, but 
association between tPA and 
improved outcome is 
sustained in those >80  
155 
Henriksen et 
al.  
Age >80  2007-2010 77 Age >80 associated with 
increased risk of sICH and 
death 
156 
      
IST-3 group 3-6 hours after 
onset and >80  
2000-2011 507+817 In total, no difference tPA vs 
placebo. Effect of tPA as 
least as good for >80 as ≤80. 
157 
Mishra et al.  Prior stroke 
and diabetes 
1998-2007 491 Better outcomes in 
thrombolysed patients with 
diabetes and/or prior stroke 
as compared to non-
thrombolysed 
158 
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Matuta et al.  Treatment with 
anticoagulants 
2003-2010 91 INR levels <2 appear safe. 
Use of heparin appear to 
increase risk of sICH 
159 
Brunner et al.  Abnormal 
baseline 
coagulation 
2006-2010 36 No increased risk of sICH in 
patients with abnormal 
baseline coagulation 
160 
Prabhakaran 
et al.  
Anti- 
coagulation 
treatment prior 
stroke  
2002-2009 13 More likely to experience 
sICH if treated with warfarin 
prior to stroke 
161 
Aleu et al.* Multiple 1995-2006 273** Risk of sICH in off-label 
thrombolysis not as high as 
presumed 
162 
Meretoja et 
al.  
Multiple  1995-2008 499 Off-label therapy not 
associated with increased 
rates of sICH, nor with poorer 
outcome, except age >80  
80 
Lopez-Yunez 
et al.  
Multiple  1996-1998 8 NINDS protocol violations 
are common and associated 
with sICH 
163 
Graham * Multiple 1996-2003 523 Rates of sICH did not 
correlate with frequency of 
protocol violations. Mortality 
correlated with frequency of 
protocol violations.  
164 
Frank et al.* Multiple 1998-2008 2755 Broad trend of more 
favorable outcome across all 
subgroups of 
contraindications 
165 
Cronin et al.  Multiple  2006-2010 80 Off-label therapy not 
associated with increased 
risk of sICH 
166 
Breuer et al.  Multiple  2006-2010 432 Off-label therapy not 
associated with increased 
risk of sICH 
167 
Mishra et al. Admission 
NIHSS  
1-4 and ≥ 25 
1998-2007 8+64 No association between tPA 
and improved outcome 
outside NIHSS 5-24. 
However, small sample sizes 
at extremes of NIHSS scale  
168 
Strbian et al.  Minor stroke 
symptoms 
1995-2010 58 No patients with NIHSS<2 
(n=58) had sICH 
148 
Baumann et 
al.  
Minor stroke/ 
regressing 
symptoms  
2002-2005 19 Withholding of tPA because 
of early regression of 
symptoms may not be 
justified 
149 
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Logallo et al.  Minor stroke 
symptoms 
2006-2013 158 No increased risk of sICH, 
treatment with tPA 
associated with excellent 
outcome 
147 
Tsivgoulis et 
al. 
Pre-treatment 
hypertension 
1996-2005 63 Higher risk of sICH in 
patients with SBP >180 or 
DBP >110 
169 
Patel et al.  Major infarct 
on CT (>1/3 
MCA territory) 
1991-1994 38 Better prognosis with tPA 
treatment after adjusting for 
NIHSS on admission 
170 
Hacke et al.  3-4.5 hours 
after symptom 
onset 
2003-2007 418 Improved clinical outcomes 
in thrombolysed patients as 
compared to placebo-group 
73 
 *Meta-analysis 
** Also included endovascular treatment 
 
Especially two of these studies have considerably increased our knowledge of off-
label thrombolytic stroke treatment. The ECASS-III trial showed in 2008 that tPA is 
safe and efficient in the time window of 3-4.5 hours after stroke onset.73 This has led 
to clinical acceptance of thrombolytic treatment beyond 3 hours after stroke onset, 
even though national guidelines still advocate the 3 hour limit.78 The IST-3 trial 
recently showed that patients older than 80 years have similar benefits of tPA 
treatment as those of younger age.157 The study could, however, not show a clear 
clinical benefit of tPA administration between 4.5 – 6 hours.  Other studies have 
found increased rates of sICH in patients treated off-label with tPA, including 
patients with anticoagulation treatment prior to stroke or hypertensive blood pressure 
before initiation of thrombolytic treatment.161, 169 In contrast to these findings, a large 
retrospective study recently demonstrated improved outcomes of off-label tPA 
treatment in patients on anticoagulants with INR levels ≤ 1.7 as well as patients with 
hypertensive blood pressure before thrombolytic treatment.165   
In total, our results combined with these prior findings indicate that some of the 
contraindications to tPA may be too conservative and that the strict adherence to 
these guidelines could preclude potentially life-saving treatment to eligible patients. 
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Future guidelines should consider updating its recommendations more accordingly to 
recent evidence and real-world experience.  
 
A more efficient thrombolysis 
When it comes to recanalization, endovascular intervention is more effective than 
intravenous thrombolysis alone. Approximately 43% of the occlusions are 
recanalized with intravenous tPA, largely depending on clot site and origin.60 The 
recanalization rates of mechanical thrombectomy and intra-arterial thrombolysis are 
stipulated to 84% and 63%, respectfully. 60 However, three recent randomized trials 
comparing endovascular treatment to standard intravenous thrombolysis failed to 
show a clinical benefit of endovascular therapies, even though recanalization rates 
were higher in this group.88-90 If recanalization is strongly associated with clinical 
outcome and endovascular treatment achieves higher recanalization rates, why did 
endovascular treatment fail to show a clinical benefit? There may be several 
explanations to this discrepancy, yet the most important factor may be time.171 
Initiation of endovascular therapy is time consuming. There is no benefit in 
recanalization if it occurs too late, regardless if the recanalization occurs through 
thrombectomy, thrombolysis or spontaneously. At least two therapeutic points can be 
derived from these disappointing results. Firstly, time is still crucial in acute ischemic 
stroke. This highlights the need for efficient and time-saving strategies to reduce 
door-to-needle time, including up-to-date guidelines regarding indications and 
contraindications to tPA. Secondly, as intravenous thrombolysis will continue to 
represent first-line treatment in ischemic stroke, research on increasing its efficiency 
is important. Advances have already been made in this field. Tenecteplase appears as 
a promising thrombolytic agent with a higher fibrin-specificity than tPA.172 This drug 
has proved to be safe and more efficient than tPA in trials of selected stroke 
patients.172-174 A phase III trial may confirm its superiority in a more general ischemic 
stroke population. Such a trial is currently being performed as a multi-center study in 
Norway (NOR-TEST).175 Another way to potentiate the recanalizing effect of 
intravenous thrombolysis is by the use of ultrasound. This method is called 
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sonothrombolysis and the supplement of sonothrombolysis with intravenous 
thrombolysis has shown to increase rates of recanalization and improve outcomes in 
selected groups of stroke patients.176 A trial of sonothrombolysis including a more 
general stroke population is currently being conducted in Bergen (NOR-SASS). 
 
Higher temperature 
Another way of achieving better recanalization rates and clinical improvement with 
intravenous thrombolysis may be based on temperature. Our findings point to a 
beneficial effect of higher body temperature as we found an increased body 
temperature being independently associated with major neurological improvement 
after 24 hours (paper IV). These results suggest an improved clot lysis and 
recanalization with tPA at higher body temperatures. This hypothesis is, however, not 
optimally addressed since imaging data of recanalization was not performed. Instead, 
major neurological improvement was used as a surrogate marker of successful 
recanalization. The use of major neurological improvement as a surrogate marker is 
in line with the close association between recanalization and dramatic neurological 
improvement found in Doppler-controlled studies.62, 63, 177   
Our findings may strike as surprising and counter-intuitive considering the vast 
amount of evidence on low body temperature being neuroprotective.178-180 A number 
of prior studies have looked into the relationship between body temperature and 
stroke outcome and many have found an association between high body temperature 
and poor outcome (table 4).  There may, however, be two explanations for the 
discrepancy between these findings and our findings. Our study included patients 
admitted within the very first hours after stroke onset, whereas most previous studies 
have analyzed the association of body temperature measured beyond the first hours of 
ischemic stroke and patient outcomes. Body temperature may have a different impact 
on ischemic stroke outcomes in different time-windows. In the acute phase of 
ischemic stroke, a beneficial effect on clot lysis may outweigh the potential 
neuroprotective effect of lower temperatures.109 Another important difference 
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between our study and some of the prior studies is thrombolytic treatment. All 
patients in our study were treated with intravenous tPA. Body temperature may have 
a different impact on outcome in patients treated with tPA as compared to those not 
treated with tPA. Prior in-vitro studies support this assumption, as the thrombolytic 
effect of tPA decreases with decreasing temperatures.105, 106 Our results are also in 
conformity with another recent retrospective study where body temperatures of 37.0 
°C or higher was associated with improved outcomes at 3 months in ischemic stroke 
patients treated with tPA, suggesting a larger benefit of intravenous thrombolysis at 
higher temperatures.181  
 
Table 4: Studies of associations between body temperature and outcome in ischemic stroke. 
Authors Hours 
onset-
adm. 
tPA Inclusio
n period 
N  Ischemic 
stroke / 
ICH 
Conclusion Ref 
Lees et al.  <3 h Yes 1998-
2007 
1980 Ischemic No evidence of 
influence of body 
temp. on tPA 
response. However, 
temp 37-37.5 higher 
effect of tPA than 
≤35.5 
110 
Blinzler et al.  <3 h Yes 2006-
2009 
320 Ischemic Trend towards higher 
admission temp. in 
patients with early 
complete 
neurological recovery 
182 
Tiainen et al.  <4.5 h Yes 1995-
2008 
985 Ischemic Admission temp. 
higher in patients 
with good outcome.. 
Increasing temp. 
over 24 hours 
associated with 
worse prognosis 
183 
Reith et al. <6 h No 1991-
1993 
390 Both For each 1 C° 
increase in temp, the 
relative risk of poor 
outcome rise by 2.2  
184 
Kammers- 
gaard et al.  
<6 h No 1991-
1993 
390 Both Low temp. on 
admission predictor 
of good short-term 
outcome 
185 
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Boysen et.al  <6 h No 1998-
2000 
725  Both Increased admission 
temp. no influence 
on outcome at 3 
months. Temp. at 12 
hours associated 
with poor outcome 
102 
Ridder et al.  <6 h Yes 2003-
2008 
647 Ischemic Baseline temp ≥37.0 
C° associated with 
improved outcomes 
at 3 months 
181 
Hemmen et 
al.  
<6 h Yes Pub. 
2010 
59 Ischemic No clinical effect of 
endovascular cooling  
186 
De Georgia 
et al.  
<12 h 56% 2001-
2002 
40 Ischemic Endovascular cooling 
induced moderate 
hypothermia. 
Outcomes similar in 
cooling group and 
placebo group 
187 
Hertog et al.  <12 h 21% 2003-
2008 
1332 Both No relation 
admission temp. and 
poor outcome. 
Increased temp. in 
first 24 hours 
associated with 
worse outcome 
103 
Hertog et al.  <12 h 22% 2003-
2008 
1400 Both No overall effect of 
paracetamol on 
outcome. Post hoc 
showed beneficial 
effect in patients with 
temp 37-39 C° 
104 
Kasner et al.  <24 h 15% 1997-
2000 
39 Both No clinical 
improvement of 
acetaminophen to 
afebrile patients 
188 
Hertog et al.* <24 h Partly 1997-
2004 
423 Both  No beneficial effect 
of pharmacological 
or physical 
temperature-lowering 
therapy 
92 
Castiollo et 
al.  
<24 h No <1998 297 Ischemic High body 
temperature 
associated with poor 
outcome 
 
 
 
101 
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Wang et al.  No limit No 1995-
1997 
509 Both Hyperthermia 
associated with 
increased one year 
mortality. 
Hypothermia 
associated with 
reduction in in-
hospital mortality 
189 
*meta-analysis 
 
There are several studies confirming the neuroprotective effect of hypothermia on 
different brain injuries, including ischemic stroke.96, 179, 190 There are also on-going 
phase III- trials investigating the efficacy of therapeutic cooling in ischemic stroke 
patients.191 Perhaps a potential thrombolytic effect of higher temperatures can be 
combined with neuroprotective cooling of ischemic tissue? TPA may be heated 
before intra-arterial application, as performed in a study of intra-arterial treatment of 
lower limb ischemia. 108Simultaneosly,  the brain tissue itself could be exposed to 
hypothermia. In this way, the theoretical beneficial effect of increased temperature on 
clot lysis could be combined with the advantages of cooling therapy. Another 
approach may be to initiate hypothermic treatment once recanalization has been 
achieved, as demonstrated in a recent study where hypothermia after recanalization 
was independently associated with favorable outcome.192 These possible modalities 
of future stroke therapy are of course speculative, but our results encourage 
untraditional reflections when it comes to temperature and ischemic stroke.  
 
Smokers – A special group to thrombolyse? 
Similar to the paradox of increased body temperatures improving outcomes in 
thrombolysed stroke patients, we showed that current smokers have improved 
outcomes after thrombolysis as compared to non-smokers (paper V). This 
phenomenon has also been reported in patients with myocardial infarction undergoing 
thrombolysis.114, 115, 193 A likely explanation is that smoking leads to higher intra-
arterial fibrin concentrations and thus formation of fibrin-rich clots.112 These clots are 
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more susceptible to thrombolytic treatment with tPA and are therefore recanalized 
more efficiently, resulting in improved outcomes for thrombolysed smoking stroke 
patients. Some studies have found similar findings which support the results and 
hypothesis of our study.116, 117 In a recent study, 148 patients treated with intravenous 
thrombolysis had MRA performed before and one day after thrombolytic 
treatment.116  Although the number of smoking patients was low (n=32), smoking 
was independently associated with both recanalization and reperfusion in support of 
the “recanalization-hypothesis” of smokers. Others have attributed the improved 
outcomes of smokers to other mechanisms, such as the younger age of smokers.118 
Another explanation might be that smokers are earlier mobilized due to the urge to 
smoke. Our findings contradict both these assumptions. In our population, smoking 
patients were indeed younger as compared to non-smokers. However, age was 
adjusted for in multivariate analysis, which makes it less likely that age represents the 
only explanation to our results. We did not have any data regarding early 
mobilization of smokers, but all patients follow standard operating procedure and are 
mobilized early. Short-term mRS was used as outcome parameter in the present study 
and this could theoretically have influence our results as compared to other studies 
using long-term outcomes. However, we included a “control-group” of patients who 
were admitted within 6 hours after stroke onset and not treated with thrombolysis. In 
this cohort, there was no association of improved outcomes and current smoking. 
This supports the hypothesis of improved thrombolysis leading to favorable outcomes 
in smokers treated with tPA. The non-randomized design of the study does, however, 
not prevent bias in terms of differences between the thrombolysed group and non-
thrombolysed group, making a direct comparison between these cohorts difficult.  
If thrombolysis with tPA is more efficient in patients who smoke, the next question is 
how this can be translated into clinical guidelines exploiting this benefit. Due to lack 
of data, it is hard to recommend general changes in the treatment protocol of 
thrombolysis in smokers. Nonetheless, our results and prior findings speak in favor of 
a more aggressive standpoint in thrombolysing acute ischemic stroke patients who 
smoke. In clinical practice, the knowledge of current smoking in an acute ischemic 
stroke patient may tip the balance in favor of thrombolysis if the clinician is in doubt 
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whether to treat with thrombolysis or not. Another interesting point is the time-
dependent clinical effect of tPA as shown in figure 3. Because the possible gain of 
thrombolytic treatment in smokers may be greater than in non-smokers, this graph 
could look different for smokers. The IST-III trial could not show a benefit of 
thrombolytic treatment in patients admitted between 4.5 – 6 hours after stroke 
onset.157 Future trials including smokers treated within this extended time-window 
could reveal a clinical benefit for this specific patient group under similar 
circumstances. Our findings may encourage the initiation of such studies.  
 
General limitations and strengths  
Our study has some limitations. Firstly, although recanalization is a central theme in 
the present thesis, direct imaging regarding recanalization or reperfusion was not 
systematically assessed and therefore mainly not presented. In paper I and II, 
remission of stroke symptoms is considered to reflect recanalization, although this 
hypothesis cannot be confirmed with imaging. Obtaining imaging evidence of 
recanalization systematically is, however, difficult in this patient population as many 
patients with transient ischemic deficits experience their reversible symptoms before 
hospital admission. Secondly, data analysis was done retrospectively. Thirdly, 
whereas traditional studies present three-month outcomes, we only presented short-
term outcomes. However, short-term outcomes are more directed to the stroke as such 
while potentially external factors such as infections, level of rehabilitation, family 
situation and recurrent strokes may influence long-term outcomes at three months. 
Strengths of the study include the use of a stroke registry where patients are 
prospectively included and data collected in a standardized manner with research 
quality.     
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Conclusions 
If early recanalization occurs, stroke symptoms may be transient. Approximately half 
of all patients with transient ischemic symptoms have DWI lesions on MRI. With a 
tissue-based TIA definition, these patients should be diagnosed with ischemic stroke 
and not TIA. Thus, an increased use of MRI leads to a decrease in the proportion of 
TIA. Patients with DWI lesions are more thoroughly investigated with cardiac 
examinations. An independent association between presence of DWI lesions and 
prior myocardial infarction suggests a cardioembolic stroke mechanism in these 
patients.  
Patients with transient ischemic symptoms have a different DWI distribution as 
compared to patients with persisting stroke symptoms. Transient ischemic symptoms 
are associated with cortical DWI lesions. The cortical location may be caused by 
recanalization, leading to upstream embolization of minor fragments from the 
original occlusion. 
If the occlusion persists and ischemic symptoms fail to reverse spontaneously, 
recanalizing treatment with intravenous thrombolysis could be indicated. 
Approximately half of the patients treated with tPA have one or more formal 
contraindications to thrombolytic treatment. This off-label treatment with intravenous 
tPA may be safe and efficient despite presence of contraindications. The strict 
adherence to the conservative recommendations of national guidelines could deprive 
potentially eligible patients from crucial thrombolytic treatment.  
In patients treated with tPA, a higher admission body temperature is associated with 
major neurological improvement after 24 hours, indicating a beneficial effect of 
higher body temperature on clot lysis and recanalization. This effect may outweigh 
the potential neuroprotective effect of lower body temperature in the acute phase of 
ischemic stroke treated with tPA.  
Smokers treated with tPA have a more favorable outcome as compared to non-
smokers. This association is not present in acute stroke patients not treated with tPA. 
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A likely explanation is that smokers have more fibrin-rich clots which respond more 
efficiently to thrombolytic treatment with tPA. These results suggest an aggressive 
point of view when it comes to treating smoking stroke patients with thrombolysis in 
order to achieve recanalization and a favorable outcome.  
A tissue-based definition of ischemic stroke based on careful neuroimaging has 
turned the temporal evolution of ischemic stroke into a more pathophysiological 
direction. Acute stroke treatment should be harmonized with this perspective and may 
increase its efficiency if a more customized approach is adapted based on the 
pathophysiology of arterial clots and their recanalization.  
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Appendix 
1. The modified Rankin Scale (mRS) 
2. The Oxford Community Stroke Project classification (OCSP) 
3. National Institutes of Health Stroke Scale (NIHSS) 
4. Trial of Org 10172 in Acute Stroke Treatment (TOAST) 
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